Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness

Journal of Rheumatology

Volumn 37, Issue 2, 2010, Pages 246-256

  Grcevic, Danka ^a   Jajic, Zrinka ^c   Kovacic, Nataša ^a   Lukic, Ivan Krešimir ^e   Velagic, Vedran ^b   Grubišic, Frane ^c   Ivcevic, Sanja ^a   Marušic, Ana ^d  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b KBC Zagreb   (Croatia)

^c SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^d UNIVERSITY OF SPLIT   (Croatia)

^e Split University School of Medicine ^*

Author keywords

Arthritis; Blood cells; Bone morphogenetic proteins; Gene expression; Runx2; Tumor necrosis factors

Indexed keywords

ANTIMALARIAL AGENT; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; CORTICOSTEROID; FAS LIGAND; GOLD SALT; HERPESVIRUS ENTRY MEDIATOR LIGAND; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BLOOD LEVEL; BONE METABOLISM; CELL DIFFERENTIATION; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE MARKER; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; OSTEOBLAST; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTHRITIS; BIOLOGICAL MARKERS; BONE MORPHOGENETIC PROTEINS; CORE BINDING FACTOR ALPHA 1 SUBUNIT; FEMALE; GENE EXPRESSION; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TUMOR NECROSIS FACTORS;

EID: 76649092609     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090167     Document Type: Article

References (58)

1. Koopman WJ, Moreland LW, editors. Arthritis and allied conditions: a textbook of rheumatology, 15th ed. London: Lippincott Williams & Wilkins; 2004.
2. Suematsu A, Tajiri Y, Nakashima T, Taka J, Ochi S, Oda H, et al. Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis. Mod Rheumatol 2007;17:17-23.
3. Sipos W, Pietschmann P, Rauner M. Strategies for novel therapeutic approaches targeting cytokines and signaling pathways of osteoclasto- and osteoblastogenesis in the fight against immune-mediated bone and joint diseases. Curr Med Chem 2008;15:127-36.
4. Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008;223:7-19.
5. Zhang X, Aubin JE, Inman RD. Molecular and cellular biology of new bone formation: insights into the ankylosis of ankylosing spondylitis. Curr Opin Rheumatol 2003;15:387-93.
6. Chen AL, Fang C, Liu C, Leslie MP, Chang E, Di Cesare PE. Expression of bone morphogenetic proteins, receptors, and tissue inhibitors in human fetal, adult, and osteoarthritic articular cartilage. J Orthop Res 2004;22:1188-92.
7. Lories RJ, Luyten FP. Bone morphogenetic protein signaling in joint homeostasis and disease. Cytokine Growth Factor Rev 2005;16:287-98.
8. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
9. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008;118:3537-45.
10. Sato K, Takayanagi H. Osteoclasts, rheumatoid arthritis, and osteoimmunology. Curr Opin Rheumatol 2006;18:419-26.
11. Ochi S, Shinohara M, Sato K, Gober HJ, Koga T, Kodama T, et al. Pathological role of osteoclast costimulation in arthritis-induced bone loss. Proc Natl Acad Sci USA 2007;104:11394-9.
12. Pang L, Wang L, Suo T, Hao H, Fang X, Jia J, et al. Tumor necrosis factor-alpha blockade leads to decreased peripheral T cell reactivity and increased dendritic cell number in peripheral blood of patients with ankylosing spondylitis. J Rheumatol 2008;35:2220-8.
13. Parker A, Izmailova ES, Narang J, Badola S, Le T, Roubenoff R, et al. Peripheral blood expression of nuclear factor-κB-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol 2007;34:1817-22.
14. Martinez-Lorenzo MJ, Anel A, Saez-Gutierrez B, Royo-Cañas M, Bosque A, Alava MA, et al. Rheumatoid synovial fluid T cells are sensitive to APO2L/TRAIL. Clin Immunol 2007;122:28-40.
15. Peng SL. Fas(CD95)-related apoptosis and rheumatoid arthritis. Rheumatology 2006;45:26-30.
16. Gaddy DF, Robbins PD. Current status of gene therapy for rheumatoid arthritis. Curr Rheumatol Rep 2008;10:398-404.
17. Pierer M, Brentano F, Rethage J, Wagner U, Hantzschel H, Gay RE, et al. The TNF superfamily member LIGHT contributes to survival and activation of synovial fibroblasts in rheumatoid arthritis. Rheumatology 2007;46:1063-70.
18. Ishida S, Yamane S, Nakano S, Yanagimoto T, Hanamoto Y, Maeda-Tanimura M, et al. The interaction of monocytes with rheumatoid synovial cells is a key step in LIGHT-mediated inflammatory bone destruction. Immunology 2009;128 Suppl:e315-24.
19. Dong W, Li X, Liu H, Zhu P. Infiltrations of plasma cells in synovium are highly associated with synovial fluid levels of APRIL in inflamed peripheral joints of rheumatoid arthritis. Rheumatol Int 2009;29:801-6.
20. Tardif G, Pelletier JP, Boileau C, Martel-Pelletier J. The BMP antagonists follistatin and gremlin in normal and early osteoarthritic cartilage: an immunohistochemical study. Osteoarthritis Cartilage 2009;17:263-70.
21. Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005;115:1571-9.
22. Iwamoto T, Okamoto H, Toyama Y, Momohara S. Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients. FEBS J 2008;275:4448-55.
23. Batliwalla FM, Baechler EC, Xiao X, Li W, Balasubramanian S, Khalili H, et al. Peripheral blood gene expression profiling in rheumatoid arthritis. Genes Immun 2005;6:388-97.
24. Junta CM, Sandrin-Garcia P, Fachin-Saltoratto AL, Mello SS, Oliveira RD, Rassi DM, et al. Differential gene expression of peripheral blood mononuclear cells from rheumatoid arthritis patients may discriminate immunogenetic, pathogenic and treatment features. Immunology 2009;127:365-72.
25. Sorensen LK, Havemose-Poulsen A, Sønder SU, Bendtzen K, Holmstrup P. Blood cell gene expression profiling in subjects with aggressive periodontitis and chronic arthritis. J Periodontol 2008;79:477-85.
26. Kamekura S, Kawasaki Y, Hoshi K, Shimoaka T, Chikuda H, Maruyama Z, et al. Contribution of runt-related transcription factor 2 to the pathogenesis of osteoarthritis in mice after induction of knee joint instability. Arthritis Rheum 2006;54:2462-70.
27. Wang Q, Wei X, Zhu T, Zhang M, Shen R, Xing L, et al. Bone morphogenetic protein 2 activates Smad6 gene transcription through bone-specific transcription factor Runx2. J Biol Chem 2007;282:10742-8.
28. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
29. Jajic I, Jajic Z. Umbilical extrusion in patients with ankylosing spondylitis. Scand J Rheumatol 1998;27:388.
30. Haywood KL, Garratt AM, Dawes PT. Patient-assessed health in ankylosing spondylitis: a structured review. Rheumatology 2005;44:577-86.
31. Elkayam O, Ophir J, Yaron M, Caspi D. Psoriatic arthritis: interrelationships between skin and joint manifestations related to onset, course and distribution. Clin Rheumatol 2000;19:301-5.
32. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
33. van der Heijde D, Spoorenberg A. Plain radiographs as an outcome measure in ankylosing spondylitis. J Rheumatol 1999;26:985-7.
34. Salvarani C, Olivieri I, Cantini F, Macchioni L, Boiardi L. Psoriatic arthritis. Curr Opin Rheumatol 1998;10:299-305.
35. Altman RD. The classification of osteoarthritis. J Rheumatol 1995;22 Suppl 43:42-3.
36. Grcevic D, Lukic IK, Kovacic N, Ivcevic S, Katavic V, Marusic A. Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos. Clin Exp Immunol 2006;146:146-58.
37. Pietschmann P, Rauner M, Sipos W, Kerschan-Schindl K. Osteoporosis: an age-related and gender-specific disease-a mini-review. Gerontology 2008;55:3-12.
38. Park MC, Park YB, Lee SK. Relationship of bone morphogenetic proteins to disease activity and radiographic damage in patients with ankylosing spondylitis. Scand J Rheumatol 2008;37:200-4.
39. Edwards JR, Sun SG, Locklin R, Shipman CM, Adamopoulos IE, Athanasou NA, et al. LIGHT (TNFSF14), a novel mediator of bone resorption, is elevated in rheumatoid arthritis. Arthritis Rheum 2006;54:1451-62.
40. Kim WJ, Kang YJ, Koh EM, Ahn KS, Cha HS, Lee WH. LIGHT is involved in the pathogenesis of rheumatoid arthritis by inducing the expression of pro-inflammatory cytokines and MMP-9 in macrophages. Immunology 2005;114:272-9.
41. Kang YM, Kim SY, Kang JH, Han SW, Nam EJ, Kyung HS, et al. LIGHT up-regulated on B lymphocytes and monocytes in rheumatoid arthritis mediates cellular adhesion and metalloproteinase production by synoviocytes. Arthritis Rheum 2007;56:1106-17.
42. Zhai Y, Guo R, Hsu TL, Yu GL, Ni J, Kwon BS, et al. LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest 1998;102:1142-51.
43. Matsuno H, Yudoh K, Watanabe Y, Nakazawa F, Aono H, Kimura T. Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. J Rheumatol 2001;28:22-8.
44. Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology 2008;47:249-55.
45. Ichikawa K, Liu W, Fleck M, Zhang H, Zhao L, Ohtsuka T, et al. TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol 2003;171:1061-9.
46. Kovacic N, Lukic IK, Grcevic D, Katavic V, Croucher P, Marusic A. The Fas/Fas ligand system inhibits differentiation of murine osteoblasts but has a limited role in osteoblast and osteoclast apoptosis. J Immunol 2007;178:3379-89.
47. Telegina E, Reshetnyak T, Moshnikova A, Proussakova O, Zhukova A, Kuznetsova A, et al. A possible role of Fas-ligand-mediated "reverse signaling" in pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Immunol Lett 2009;122:12-7.
48. Hayashi S, Miura Y, Nishiyama T, Mitani M, Tateishi K, Sakai Y, et al. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Arthritis Rheum 2007;56:1067-75.
49. Emery P, Gabay C, Kraan M, Gomez-Reino J. Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int 2007;27:793-806.
50. Bovin LF, Rieneck K, Workman C, Nielsen H, Sørensen SF, Skjødt H, et al. Blood cell gene expression profiling in rheumatoid arthritis. Discriminative genes and effect of rheumatoid factor. Immunol Lett 2004;93:217-26.
51. Sennels H, Sørensen S, Ostergaard M, Knudsen L, Hansen M, Skjødt H, et al. Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate. Scand J Rheumatol 2008;37:241-7.
52. Aman S, Paimela L, Leirisalo-Repo M, Risteli J, Kautiainen H, Helve T, et al. Prediction of disease progression in early rheumatoid arthritis by ICTP, RF and CRP. A comparative 3-year follow-up study. Rheumatology 2000;39:1009-13.
53. Haroon N, Tsui FW, O'Shea FD, Chiu B, Tsui HW, Zhang H, et al. From gene expression to serum proteins: biomarker discovery in ankylosing spondylitis. Ann Rheum Dis 2008. E-pub ahead of print.
54. Modder UI, Khosla S. Skeletal stem/osteoprogenitor cells: current concepts, alternate hypotheses, and relationship to the bone remodeling compartment. J Cell Biochem 20081;103:393-400.
55. Nose M, Yamazaki H, Hagino H, Morio Y, Hayashi S, Teshima R. Comparison of osteoclast precursors in peripheral blood mononuclear cells from rheumatoid arthritis and osteoporosis patients. J Bone Miner Metab 2009;27:57-65.
56. Alarcon-Riquelme ME. Role of RUNX in autoimmune diseases linking rheumatoid arthritis, psoriasis and lupus. Arthritis Res Ther 2004;6:169-73.
57. Bickel DR. Degrees of differential gene expression: detecting biologically significant expression differences and estimating their magnitudes. Bioinformatics 2004;20:682-8.
58. van Boekel MA, Vossenaar ER, van den Hoogen FH, van Venrooij WJ. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2002;4:87-93.